Healthy Skepticism Library item: 3373
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Silverman M, Lee PR, Lydecker M.
Drug promotion: the Third World revisited.
Int J Health Serv 1986; 16:(4):659-67
Abstract:
In 1973 and 1980 surveys, much of the promotion of prescription drugs in the Third World was found to be marked by gross exaggeration of clinical claims and glossing over of possible serious or fatal adverse reactions. In an expanded survey of the information distributed in 1984 to physicians in the United States, the United Kingdom, and 28 developing nations in Africa, Asia, and Latin America, striking changes were noted. Many of the pharmaceutical firms were found to be showing more restraint in limiting their claims in the Third World to those which can be supported by scientific evidence, and far more willingness to disclose serious hazards. The companies discarding a double standard in drug promotion have apparently not suffered any significant loss of profits. There is, however, evident need for further improvement by both multinational and domestic companies. The present study covered 1069 products representing 63 drug entities and fixed combinations, marketed by 303 companies.
Keywords:
*analytic survey/United States/United Kingdom/Africa/Asia/Latin America/developing countries/developed countries/commercial compendia/MIMS/PDR/Physicians’ Desk Reference/quality of information/ domestic companies/ research-based manufacturers/EVALUATION OF PROMOTION: COMMERCIAL DRUG COMPENDIA/EVALUATION OF PROMOTION: COMPARISON BETWEEN DEVELOPING AND DEVELOPED COUNTRIES/PROMOTION AND HEALTH NEEDS: PROMOTION IN DEVELOPED COUNTRIES/PROMOTION AND HEALTH NEEDS: PROMOTION IN DEVELOPING COUNTRIES
Africa
Americas
Analgesics
Anti-Infective Agents
Antidiarrheals
Asia
Cardiovascular Agents
Comparative Study
Developing Countries*
Drug Labeling/standards*
Great Britain
Humans
Psychotropic Drugs
Research Support, Non-U.S. Gov't
Vasodilator Agents
